Objectives: Identification and characterization of the genes encoding hgh-level glycopeptide resistance in enterococci h m Norwegian and Swedish humans and avoparcin-exposed Norwegian poultry.
MICSO MICw
In general first and second generation cephalosporins presented good activity, although in the case of cefaclor and cefoxitin MICso were near the breakpoint and 37% of the strains were resistant to cefminox. Third generation cephalosporins of parented administration and cefepime showed excellent activity, although MICso of ceftazidune was near the breakpoint. In the group of oral third generation cephalosporins, all the shains were susceptible to cefpodoxime but the majority resistant to cefixime and all to cefcibuten. During an outbreak of VanB enterococci on a Leukaemia unit, E. faecium was lsolated fivm two patients (isolates D and C, respectively). These isolates were identical to the outbreak strain by Pulsed Field Gel Electrophoresis (PFGE) of SmaI-digested DNA and ribotyping (rRNA probing of the PFGE gels). However, both D and C were resistant to t e i c o p h (VanA phenotype). An isolate indstinguishable h m the outbreak strain had been recovered fivm patient D seven months previously. Three plasmid profiles were observed; isolate C and the outbreak strain carried plasmids with the wnA and the vanB genes, respectively, while D carried both the vanA and wnB genes on two Merent plasmids. mnB transconjugants were obtained h m D and the outbreak strain, indcating transferable uanB resistance. The uanB plasmids in these isolates had identical patterns following EcoRV digestion and an identical firagment (2.1 kb) hybridised with a vanB probe. The plasmid profiles of D and C Mered only by the absence of this uanB phsmid h m C. These data suggest that during the outbreak, the predominant strain of E. fwcium, carrying a uanB plasmid, acquired a v a d plasmid and other mobilizable plasmids, and subsequently lost its vanB plasmid. T h study W t s the remarkable ability of E. 4ecium to acquire and lose resistance genes.
Resistance genotyping must be used in conjunction with PFGE to define fully the epidemiology of glycopeptide-resistant enterococci. Objectives: Great discussion is related to the origin of glycopeptide resistance: the result obtained at both the DNA and protein levels are in favour of an exogenous origin for high-level glycopeptide resistance in Enterococci, but results obtained by Dukta-Malen et al. showed no homology between the vanA probe and genomic DNA of saains producing teicoplanin, neither to the gene present in intrinsically resistant strains. No informations are available regarding vanB origin. These situation contrast with the stepwise changes in susceptibility to vancomycin of S. haemolyticuc which suggest an indigenous origin, by chromosomal mutation, for glycopeptide resistance. The selective pressure of the use of glycopeptides is associated with the emergence of transferable glycopeptide resistance in enterococci, but no informations are published on the possible changtng in some phenotype and genotype characteristics.
Methods: The possible development of resistance was studied by s e r d transfer, performed as follows: five serial aansfer with subinhibitory concentrations of vancomycin and teicoplanm were followed by five transfer in antibiotic h e medium. These serial transfers were repeated for six cycles at concentrations half of the MICs obtained in any previous passage. Cross induction of resistance was determined. To avoid any contamination, identification of variants were verified by API Strepto System (Bio Merieux), and, when necessary, by using PFGE analysis. Stability of the acquired induction was assessed by MIC determination after five daily passages every cycle of variants in antibiotic h e medum. The 38 uncontrolled studies involved 658 patients with confirmed CNS infections. The chicallbacteriological responses in these studies were: endocarditis (92%; loo%), FNEhne mfections (87%; 89%), bacteraemia 96% 96%), bone/joint (86%; 89%). skin and soft tissue (97%; 93%). and neonates/paediatrics (96%; 96%) with overall responses (93%; 93%).
Results

Conclusions:
Teicoplanin is as effective as other antibiotics in the treatment of CNS infections and has other advantages in terms of once dady administration, intramuscular use and improved tolerability. Susceptibility data and c h c a l outcome in 3 defined types of infection treated with teicoplanin (vascular-access bacteremia P A C T , bone and joint infection PJ and skin/soft tissue infection [SST)
Efficacy of Teicoplanin in Infections
were analysed to determine the relationship between dose, serum level, MIC and outcome. In total, data h m 459 patients were available for analysis (47 BACT, 149 BJ and 263 SST). All patients received teicoplanin at doses ranging h m 3 to 12 mg/kg. In BACT, 43 of 47 (91.5%) patients were cured; trough serum levels exceeded MIC by a factor of 4 in most cases. The major pathogens were S. aureus and S. epidmidis; in 3 cases caused by S. hemolyticus, with MICs of 2 (n = 1) and 16 mg/L (n = 2), the outcomes were two cures and one failure (MIC 16 mg/L). In BJ, there was no sigdicant relationship between MIC and outcome. Treatment failed in 3/25 chronic osteomyelitis and 1/29 acute osteomyelitis caused by S. (IUreus (MIC range 0.25-2, median trough level 15 mg/L) suggesting that underlying factors were more predictive than pharmacodynamics. Similarly, in SST, there was no significant relationshp between dosage, serum level or MIC of the infecting pathogen and &cal outcome. However, higher doses of teicoplanin ( 6 1 0 mg/kg) were more successful in lnfections with mixed aetiology (45/59, 76% vs 50/52,96%). In general, whilst there was a suggestion ofhigher cure rates in infections caused by more sensitive pathogens, other factors such as extent of vascularisation or use of combination therapy may be more of greater importance. Early preparations of vancomycin were associated with a high incidence of AEs, which have been sigdicantly reduced by improved purification. Teicoplanin has a similar structure to vancomycin, but a longer half life, inttavenous and intramuscular formulations, and reduced nephmtoxicity in combination with aminoglycosides. The most common AEs in a series of 3377 patients were hypersensitivity (2.6%), abnormal liver function (1.7%), fever (0.8%). local intolerance (1.6%), abnormal renal function (0.6%) and ot&city (0.3%). Of 6696 patients on file, 3.1% experienced rash, 2% fever, 1% rigors, 1% diarrhoea and 1% nausea. Comparative trials of teicoplanin and vancomycin in the USA (825 patients) showed similar incidence of AEs for the two agents. In 14 comparative trials, there were 40/965 (4.1%) instances of nephmtoxicity among patients receiving teicoplanin at 6 mg/kg/day plus an aminoglycoside compared to 75/951 (7.9%) patients receiving vancomycin plus aminoglycoside. Red-man syndrome is observed in up to 47% patients following rapid infusion of the fint dose of vancomycin and can be avoided by slow infusion rates of 30-60 min. The syndrome, which may be due to histamine release, also occurs with highly purified vancomydn, suggesting the molecule rather than impurities are responsible. Only 3/6696 (0.04%) patients receiving teicoplanin have experienced red-man symptoms. Fever and rash normally occur at 2-3% with teicoplanin but can occur at up to 28% following prolonged treatment. Neutropenia is tare at normal dosages (0.0743%) but the incidence can rise in patients receiving very high doses. Teicoplanin is not associated with severe liver toxicity or gastro-intestinal AEs.
Conclusion: Within the class of glycopeptides, teicoplanin has a favourable safety profile, allowing bolus adrmnistration and reducing the requirement for routine serum monitoring. Comparative serum concentration data from 3 clinical trials of teicoplanin (T) vs vancomycin (V) have been reviewed. In total, 255 patients were available for data analysis: 123 T and 132 V. Groups were well-matched for age, sex and weight. Infections treated included FNE, line dections and septicemia. There was no diEerence between treatment groups in terms of &cal (T, 83.5% success; V, 82% success) or bacteriological response p. 81% eradtcation; V, 87% eradication). Mean dady doses were: T, 380 mg/5.8 mg/kg (range 124-1080 mg) and V, 1888 mg/29.1 mg/kg (750-3125 mg). Most patients received monotherapy or combination therapy with two other antibacterials, including aminoglycosides, and c. 15% received aminoglycosides prior to glycopeptide theram. Estimated creatinine clearance values (CrCl) were lower in T patients at baseline (102 vs 115 mL/min) but changed signlficantly more during treatment with vancomycin (-6.6, -6.5% change vs -23.1, -20.1% change; p < 0.05). Mean trough serum levels, by dose for T, were: <5 mg/kg/day, 6.8 f 4.8 m g k , 5-7.5 mg/kg/day, 9.3 f 5.9 mg/L. Mean trough levels for V were 11.9 f 7.7 mg/L. Levels for both glycopeptides were hgher during days 4-7 of treatment than during days 1-3. High mean through levels were achieved in elderly patients (>65, n = 44) with V (15.9 mg/L) but not T (6.2 mg/L). These results confirm the comparable efficacy of T and V, that through levels can be variable for both glycopeptides but are close to target ranges, and that V is associated with more decreases in renal function, as measured by CrCl, than T. Analysis of the combined results indicated that more than three quarters of the patients in each of the treatment groups had a successful c h c a l and bacteriological response to therapy, with no Merence between treatment groups. There were markedly fewer reports of adverse events in patients receiving teicoplanin (14%) than in those receiving vancomycin (22%). On the basis of MlCs for 50% of the strains tested, teicoplanin was 2-8 fold more active against all gram-positive cocci as compared to vancomycin. There was a good correlation between two susceptibility methods except two intermediately teicoplanin susceptible isolates with disk method being M y susceptible with agar dilution. There was no t e i c o p h resistant isolate before the marketing of the drug. Objectives: To determine whether the use of oral vancomycin is associated with an increased fkquency of vancomycin-resistant r ncroorganisms, and to determine faecal concentrations of vancomycin and correlate the levels with quantitative and quahtative alterations of the intestinal microflora.
Methods: Twenty healthy volunteers received cefuroxime axed tablets (250 mg) perorally b i d . for 1 week, and 10 of these received subsequently vancomycin capsules (125 mg) perorally q.i.d. for 7 days. Faecal samples were collected h m all subject on days 0, 7, 10, 14,21, and 28.
Results: The concentration of vancomycin in feces after 1 week vancomycin administration was high (mean (SD) 520 (197) mg/kg), which correlated with the ecological disturbances noted in the vancomycin group. Vancomycin adminutration resulted in a rapid decrease of intestinal Enterococcus faecium, Enterococcus faecalis and Enterococcw durans (P 5 0.05), and a selection of motile enterococci with decreased susceptibility to vancomycin (Enferocoms gallinarum and Enferococrus rassilfiuus, MIC 4-16 mg/L) (P 5 0.01). There was also a significant overgrowth of vancomycin resistant Pediococcus sp. and lactobacilli, as well as of Mebsiella sp., Citrobacter sp. and Enterobacter sp. ( P 5 0.01), while bifidobacteria and Bacteroides sp. were sigdicantly reduced in numbers during vancomycin administration. All motile enterococci carried the w n C gene, whde none of these strains carried uanA or uanB gene.
Conclusions: Administration of vancomycin sigdcantly selects for intestinal gram-positive bacteria with decreased susceptibility to vancomicin.
Successful Treatment of Vancomycin-Resistant Enterococcal (VRE) Infections with Teicoplanin
I. Warding. Thackelay's Ltd, Devizes, UK
During a compassionate program in the USA, 12 patients were treated with t e i c o p h n for infections caused by W. Infections (mean duration 31d) treated included sepsis (6), abdominal abscess (3), endocarditis, wound infection and mfected ulcer (1 each). Patients had mean age 49.3 y (range 20-82) and multiple underlying conditions including organ transplants, leukemia and renal/hepatic failure. All had received previous antibacterial therapy with one or more agents (vancomycin in 8 cases)., and all received concomitant antibacterials with teicoplanin (usually aminoglycosides). Teicoplanin was given on a mg/kg basis, following a loadmg dose, with dady doses ranging from 200 to 1450 mg. Mean duration of treatment was 36d (range 7-89). Pathogens included Efaecium Q, Enferococcus spp. (3), E. duram and E. cacsellpaous (1 each). All were resistant to vancomycin (MIC range 1 6 2 5 6 mg/L) and susceptible to teicoplanin, showing vanB and vanC phenotypes. Four patients had mixed mfections; the patient with resistant E. durans also had a vancomycin-susceptible E. faecium. Pathogens were grown finm blood culture in 8 cases and tissue specimens in the remainder. Nine patients were cured, one improved and two faded treatment with teicoplanin. Pathogens were eradicated in 10 patients; one experienced persistence of an Entemwms spp. from an abdominal abscess, and both E. duram (vancomycin-resistant) and E. faecium (susceptible) persisted in another patient with sepsis. This patient died subsequently and was found to have endocarditis on autopsy. Only one patient experienced a teicoplanin-related AE (rash). It is concluded that t e i c o p h is effective and safe in the treatment of infections caused by VRE. In 1995, 826 consecutive Gram-positive isolates were collected at eight centres in Switzerland and their susceptibilities to teicoplanin and vancomycin determined using standard agar dilution methodology. Teicoplanin was particularly active against Streptococcus spp (n mg/L compared to an MIC9o of 0.5 mg/L for vancomycin. Similarly, teicoplanin (MIGO: 0.5 mg/L) was eight fold more active than vancomycin against Enterococcus spp (n = 141). Two of the twelve strains of E. faecium collected displayed the vanA phenotype and were resistant (MIC 64 mg/L) to both teicoplanin and vancomycin. A further two strains of E. faecium displayed intermediate resistance to vancomycin (MIC 8 mg/L; vanEI phenotype). Against staphylococci, teicoplanin was two fold more active than vancomycin against S. aureus (n = 303) with an of 1 mg/L but nw fold less active against coagulase negative species (n = 122) with an M Q O of 4 mg/L. For all staphylococci, teicoplanin exhlbited an extended MIC range with a maximum value of 16 mg/L. Among other species collected only one strain, a Pediococncc sp., was resistant to teicoplanin and vancomycin. On the basis of MIC90 criteria, vancomycin was 2-4 times more active than teicoplanin against staphylococci whereas teicoplanin was at least two fold more active against streptococci. Teicoplanin was generally four to eight fold more active than vancomycin against the majority of Enterococcus spp. The incidence of enterococci resistant to teicoplanin (0.62%) and vancomycin (0.93%) was low. At present only the glycopeptides teicoplanin and vancomycin retain, in most sites, a consistent activity against multi-drug resistant Gram-positive pathogens responsible for serious infections in the community and in n o s o c o d settings. Thus, monitoring their continuous efficacy becomes essential since the clinicians are accustomed to use these drugs on an empirical basis. In 1995 a large multicenter study enrolling 70 laboratories in 9 European countries has analysed 6824 Gram-positive isolates for susceptibility to the two glycopeptides. In Italy, besides teicoplanin and vancomycin, the in vifro activity of several other relevant drugs was assessed by an agar dilution method (NCCLS) on the collection of strains (807) sent to this coorh a t i n g laboratory. Percent susceptible organisms at the breakpoints (NCCLS, 1995) Thts SUN^ confirms that teicoplanin is more active than vancomycin on Enterococci and that it displays in practice comparable potency against the Staphylococci. In accordance with the data obtained in other countries it may be concluded that usage of the two glycopeptides, as occurring in Europe, may delay the appearance and spread of glycopeptide-resistant Gram-positive pathogens as experienced in other regions of the world where only one molecule is employed. One possible mechanism for this may be ascribed to the fact that vancomycin can easily induce organisms carrying the VanB phenotype to f d blown resistance while teicoplanin is devoid of this untoward effect. Methods: The susceptibility data b m 4 collaborative Studies (each comprising more than 20 centres) conducted in 1983 (prior to the introduction of any fluoroquinolone), 1986 (after introduction of norfloxacin and ofloxacin in Germany), 1990 (after introduction of ciprofloxacin in Germany), and 1995 were analyzed. Uniform standard methods for idenbfication of the bacteria and susceptibility testing were used. MICs were determined by the broth microdilution method. A total of 14,960 strains were under investigation. Data are presented for ciprofloxacin regarded as a representative fluoroquinolone.
Teicoplanin and Vancomycin in Switzerland
Results: Considering 2 4 mg/l as a breakpoint for resistance to ciprofloxacin the incidence of resistant strains of Enterobacterimeae remained below 1% until 1990, but increased to 3.8% (E. coli 5.2%) in 1995. The resistance rates in I! aeruginosa were 0.7%. 1%, 6.4%, and 11.9%, in S. aureus 0%. 0.5%, 6.2%, and 12.8%, and in E.faecalis 2.2%, 0.7%, 7.7%, and 28.9%. The resistance rate in CNS increased b m 19.6% (1990) to 44.5% (1995) . In the latest study E . faen'um, M R S A , and M R -C N S had the highest resistance rates (73.1%, 89.6% and 69.8%, respectively).
Conclusions: The increasing consumption of fluoroqinolones seems to select resistant populations. Fluoroquinolone resistance has emerged in Central Europe. Objectives: To determine the rate of ciprofloxacin (CIP) resistance by using the ATI3 system in E . coli isolates collected from two multicenter surveys of l l Belgian hospitals and to define clonal diversity and gyrase mutation in CIP-E. coli isolates.
Central
Methods: CIP-R isolates were analysed by genomic typing (Arbiuary Primer-PCR analysis using ERIClR and ERIC2 primers and PFGE analysis using XbaI). Detection of gyrA codon 83 mutation was done by using PCR amplification of the gyrA QRDR region and H i n j RFLP analysis.
Results: The rate of CIP-R in E. coli isolates increased from 121520 (2%) in 1991 to 27/504 (5%) in 1993 (p -= 0.01). CIP MICs ranged &om 4 to 64 wg/ml. AP-PCR analysis discriminated 14 genotypes and PFGE typing delineated 15 major types among 23 a d b l e CIP-R isolates fiom 1993 survey. Genotypes appeared geographically dispersed. All CIP-R isolates exhibited the most fiequently reported mutation in codon 83 ofByrA. Conclusions: These data indicate that CIP resistance is increasing among'E. coli isolates b m hospitalized patients in Belgium. Genomic diversity suggests that polyclonal emergence of CIP-R mutants is the predominant mechanism. Although a common ByrA mutation was found in CIP-R strains, the presence of additional mutations in gyrA and/or p a C genes may explain the high resistance displayed by the majority of strains.
